Abstract
Polymorphisms in chemokine receptors play an important role in the progression of cervical intraepithelial neoplasia (CIN) to cervical cancer (CC). Our study examined the association of CCR2-64I (rs1799864) andCCR5-Δ32 (rs333) polymorphisms with susceptibility to develop cervical lesion (CIN and CC) in a Brazilian population. The genotyping of 139 women with cervical lesions and 151 women without cervical lesions for the CCR2-64I and CCR5-Δ32 polymorphisms were performed using polymerase chain reaction-restriction fragment length polymorphism. The individuals carrying heterozygous or homozygous genotypes (GA+AA) for CCR2-64I polymorphisms seem to be at lower risk for cervical lesion [odds ratio (OR) = 0.37, p = 0.0008)]. The same was observed for the A allele (OR = 0.39, p = 0.0002), while no association was detected (p > 0.05) with CCR5-Δ32 polymorphism. Regarding the human papillomavirus (HPV) type, patients carrying the CCR2-64Ipolymorphism were protected against infection by HPV type 16 (OR = 0.35, p = 0.0184). In summary, our study showed a protective effect ofCCR2-64I rs1799864 polymorphism against the development of cervical lesions (CIN and CC) and in the susceptibility of HPV 16 infection.
Highlights
Infections by oncogenic types of human papillomavirus (HPV) are found in 99% of women with cervical cancer (CC) (de Oliveira et al 2013)
The aim of this study was to analyse the association for CCR2-64I and CCR5-Δ32 polymorphisms with development of cervical intraepithelial neoplasia (CIN) or CC in women infected by HPV from Northeast Region of Brazil
When considering the prevalence of type-specific high-risk HPV (HR-HPV) infection, we observed that 38.8% of the patients had HPV 16, 22.3% HPV 18, 2.9% HPV 31, 3.6% HPV 33, and 14.4% other HPV types
Summary
Infections by oncogenic types of human papillomavirus (HPV) are found in 99% of women with cervical cancer (CC) (de Oliveira et al 2013). This virus is classified as the most important carcinogenic risk factor according to the criteria of the International Agency for Research on Cancer (Bonanni et al 2015). Chemokine receptor (CCR) is the major receptor for the chemokine and their ligands are the macrophage inflammatory protein (MIP)-1α/chemokine ligand (CCL), MIP-1β/CCL4, and regulated on activation, normal T cell expressed and secreted/CCL5 (Lehner 2002, Al-Abdulhadi & Al-Rabia 2010, Ahmadabadi et al 2012). Conflicting results on the role of the CCR5 and CCR2 polymorphisms in the development of the CC have been reported so far (Coelho et al 2005, Zheng et al 2006, Ivansson et al 2007, Chatterjee et al 2010)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
